Foghorn Therapeutics (FHTX) vs Stablecoin Development (SDEV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Foghorn Therapeutics (FHTX) has outperformed Stablecoin Development (SDEV) over the past year, losing 55.8% versus a loss of 66.8%. Over five years, FHTX leads with a -83.9% price change compared with -99.9% for SDEV. Foghorn Therapeutics is the larger company by market cap ($118.2 million vs $103.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FHTX | SDEV |
|---|---|---|
| Share price | $1.99 | $1.99 |
| Market cap | $118.18M | $102.99M |
| 1-day change | -4.78% | -28.42% |
| YTD return | -63.15% | -92.94% |
| 1-year return | -55.78% | -66.83% |
| 5-year return | -83.93% | -99.94% |
| EPS (TTM) | $-0.98 | $-21.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.61 | $99.75 |
| 52-week low | $1.79 | $0.78 |
| Distance from 52-week high | -73.85% | -98.01% |
| Analyst consensus | buy | — |
| Avg. price target upside | +201.51% | — |
| Average volume | 616.68K | 11.42M |
| Shares outstanding | 59.39M | 51.75M |
| Employees | 106 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FHTX has outperformed SDEV by 11.1 percentage points over the past year.
About Foghorn Therapeutics
FHTX stock →Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
About Stablecoin Development
SDEV stock →Stablecoin Development Corporation engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
FHTX vs SDEV FAQ
Which is bigger, Foghorn Therapeutics or Stablecoin Development?
Foghorn Therapeutics (FHTX) is larger, with a market capitalization of $118.18M compared with $102.99M for Stablecoin Development (SDEV).
Which stock has performed better over the past year, FHTX or SDEV?
FHTX returned -55.78% over the past 12 months, compared with -66.83% for SDEV (price return, excluding dividends). Past performance does not predict future results.
Are Foghorn Therapeutics and Stablecoin Development in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.